As GLP-1 RAs ripple into adjacent sectors, from brain health to renal disease, competition is heating up, and the appetite for next-generation therapies is growing
The fixes are unglamorous and effective: slower dose titration, smaller and lower-fat meals, soluble fiber (psyllium binds bile acids surprisingly well), and hydration with electrolytes
Key findings from the analysis include: Lower total hospitalizations with semaglutide versus placebo for any indication Reduced admissions related to serious adverse events Fewer cumulative days spent in hospital across all causes Consistent benefits across subgroups defined by age, sex, and baseline BMI The trial cohort was characterized by a high baseline burden of cardiovascular morbidity and health care utilization, underscoring the clinical relevance of these findings
Abbreviations CoA, Coenzyme A
(1) At The Peer Group, we offer both semaglutide and tirzepatide
Touliatos is currently available for consultation